AIM: COG Company Description
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally.
The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval.
It also offers eCOA, a data management tool for clinical scales which supports questionnaires and issue resolutions; and provides cognitive kit for detecting fluctuations in brain health.
In addition, the company provides voice analysis tools for monitoring neurological and psychiatric disorders; eConsent, a patient consent solution; and Clinpal, an application for managing patients workflows.
Further, it offers AQUA, a speech analysis platform for clinical scales. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.
Country | United Kingdom |
Founded | 2012 |
Industry | Medical - Healthcare Information Services |
Sector | Healthcare |
Employees | 119 |
CEO | Matthew Stork |
Contact Details
Address: Tunbridge Court Cambridge, CB25 9TU United Kingdom | |
Website | cambridgecognition.com |
Stock Details
Ticker Symbol | COG |
Exchange | London Stock Exchange AIM |
Fiscal Year | January - December |
Reporting Currency | GBP |
ISIN Number | GB00B8DV9647 |
SIC Code | 8200 |
Key Executives
Name | Position |
---|---|
Matthew Stork | Chief Executive Officer |